1. In Vivo
  2. >>Leadership

Finger On The Pulse: The State Of Biopharma Leadership

Pharma Leaders Focus On Providing A Clear Vision In The Face Of Uncertainty

 
• By Chloe Kent

In Vivo asked six biopharma figureheads to share their thoughts on the state of leadership in the life sciences space, exploring the qualities of a great leader, how recent years have shaped this role within the industry and the challenges ahead.

Graphic featuring headshots of all the interviewees
Roivant CEO Matt Gline, UPS Healthcare VP of sales Cathy O'Brien, Pfizer SVP of commercial strategy & innovation Andy Schmeltz, Celltrion USA CEO Tom Nusbickel, Ipsen chief business officer Phillipe Lopes-Fernandes, Sandoz CEO Richard Saynor • Source: Shutterstock

Recent years have seen the role of a biopharma industry leader alter drastically, with events like the COVID-19 pandemic and the war in Ukraine reshaping the day-to-day operations of the sector, from drug distribution to the dominance of remote working. In Vivo caught up with six leaders across the space – from big pharma to generics and biosimilars developers – to get their take on the changing role of a biopharma industry leader.

Matt Gline, CEO of growing biotech company Roivant Sciences Ltd., said: “That’s a hard question and I still spend...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Rising Leaders 2025: Kura Oncology’s Mollie Leoni On Setting Precedent, Not Following It

 
• By Jo Shorthouse

Kura Oncology's new chief medical officer discusses her path to leadership, the company's advancing AML pipeline, and her methodical approach to developing treatments for underserved oncology indications.

Finding The Fire: AltruBio’s Novel Approach To Autoimmune Disease

 
• By David Wild

CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.